Portal de Periódicos da CAPES

Comparison of Roche Cobas Amplicor and Abbott LCx for the Rapid Detection of Chlamydia trachomatis in Specimens From High-Risk Patients

1998; Lippincott Williams & Wilkins; Volume: 25; Issue: 1 Linguagem: Inglês

10.1097/00007435-199801000-00009

1537-4521

Ólafur Steingrı́msson, Kristín Jónsdóttir, Jón Ólafsson, SIGFÚS M. KARLSSON, Rannveig Pálsdóttir, STEINGRÍMUR DAVÍDSSON,

Bacterial Identification and Susceptibility Testing

Objective: To evaluate two automated amplification systems for the detection ofChlamydia trachomatisin urogenital specimens, the Cobas Amplicor (Roche Diagnostic Systems, Branchburg, NJ) and the LCx (Abbott Laboratories, Abbott Park, IL). Study Design: The two systems were compared testing specimens from 302 high-risk patients, including 98 female cervical swab specimens and 204 male urine specimens. The patients attended the state STD clinic in Reykjavik, Iceland, either because of symptoms or as a result of contract tracing. Results: The prevalence ofC. trachomatisinfection was 15.3% in women and 13.2% in men. For the male urine specimens, the sensitivity and specificity were 100% and 99.4% for the Cobas Amplicor and 74.1% and 100% for the LCx. In the cervical swabs, both systems detected all 15 true-positive specimens. The internal control used with the Cobas Amplicor detected inhibition in 2% of the male urine and 20% female cervical swabs, respectively. Conclusion: The Cobas Amplicor demonstrated slightly better sensitivity than LCx in male urine specimens. Both systems offer the benefits of automation for routine diagnostic testing.